Table 3.
Randomized controlled studies providing evidence of glycemic efficacy of isCGM
| Study | Study design | Study population | Diabetes type | Insulin regimen | Baseline glycemic status (CGM vs. SMBG) | Primary outcomes | Results (CGM vs. SMBG) |
|---|---|---|---|---|---|---|---|
| Bolinder et al. (2016) [28] | Parallel, 6 months | 241 adults | T1DM | CSII, MDI | HbA1c ≤7.5% | Change in time in hypoglycemia (<70 mg/dL) between baseline and 6 months | Adjusted between-group differences: −1.24 hour (P<0.001) |
| Mean HbA1c: 6.7% vs. 6.7% | 3.38–2.03 hours vs. 3.44–3.27 hours | ||||||
| Oskarsson et al. (2018) [29] | Parallel, 6 months | 167 adults | T1DM | MDI | HbA1c ≤7.5% | Change in time in hypoglycemia (<70 mg/dL) between baseline and 6 months | Adjusted between-group differences: −1.65 hour (P<0.001) |
| Mean HbA1c: 6.7% vs. 6.7% | 3.44–1.86 hours vs. 3.73–3.66 hours | ||||||
| Haak et al. (2017) [27] | Parallel, 24 weeks | 224 adults | T2DM | CSII, MDI | HbA1c 7.5%–12.0% | Difference in HbA1c at 6 months | Adjusted between-group differences: −0.29% (P=0.8222) |
| Mean HbA1c: 8.7% vs. 8.9% | 8.37% vs. 8.34% |
isCGM, intermittent scanning continuous glucose monitoring; SMBG, self-monitoring blood glucose monitoring; T1DM, type 1 diabetes mellitus; CSII, continuous subcutaneous insulin infusion; MDI, multiple daily insulin injection; HbA1c, glycosylated hemoglobin; T2DM, type 2 diabetes mellitus.